Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The PemBla Trial has now received OCTRU Green Light approval and can begin recruitment.

This is a parallel group, open label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab. The main study will be preceded by a single-institution safety run-in with intra-patient dose escalation of intravesical pembrolizumab performed in paired patient cohorts to confirm the safety and tolerability of intravesical pembrolizumab and the dose to be used in the randomised phase.